OBJECTIVE: Aim: To examine potential protective effect of Tirzepatide against obesity-induced metabolic dysfunction and hepatic inflammatory and apoptotic responses.
PATIENTS AND METHODS: Materials and Methods: A total of 28 adult male Sprague-Dawley rats were employed and divided into four groups, normal control group involved seven rats fed a regular diet, while other rats received a high fat diet. Obese rats were separated into three groups after eight weeks of high fat diet: obesity, Tirzepatide (10 nmol/kg) s.c and vehicle groups, and treated for four weeks. Data regarding body weight, blood glucose, serum insulin, liver enzymes, and TNF-α, IL-1β and caspase-3 levels in the liver tissue were obtained.
RESULTS: Results: results revealed that Tirzepatide-treated obese rats exhibited significantly reduced body weight, blood glucose, serum insulin ALT, triglyceride, VLDL levels. Additionally, liver specimens from Tirzepatide group demonstrated lower levels of TNF-α, IL-1β and caspase-3 compared to obese untreated rats.
CONCLUSION: Conclusions: It concluded that Tirzepatide treatment mitigates the metabolic dysregulations induced by High Fat Diet, additionally; it ameliorates the inflammatory and apoptotic responses in hepatic tissue triggered by High Fat Diet.